Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

U.S. Funds Antibiotics Work At AstraZeneca …

by Ann M. Thayer
September 28, 2015 | A version of this story appeared in Volume 93, Issue 38

The U.S. Biomedical Advanced Research & Development Authority (BARDA) and AstraZeneca will develop drugs with dual uses in treating antibiotic-resistant infections and illnesses caused by bioterrorism agents. BARDA will provide $50 million up front and up to $170 million in total over five years to support a portfolio of drug candidates. A combination of two existing antibiotics, aztreonam and avibactam, that AstraZeneca is testing in Phase II clinical trials will become the program’s first candidate. Earlier this year AstraZeneca said it plans to spin off its antibiotics discovery efforts. In 2013, BARDA set up a similar program with GlaxoSmithKline. BARDA and GSK have since advanced an antibiotic toward Phase III trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.